Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?
Open Access
- 1 May 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal Of Hypertension
- Vol. 38 (5), 781-782
- https://doi.org/10.1097/HJH.0000000000002450
Abstract
An abstract is unavailable. This article is available as a PDF only.This publication has 10 references indexed in Scilit:
- MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptidesAmerican Journal of Physiology-Cell Physiology, 2008
- Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 ratsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2006
- Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2Circulation, 2005
- Upregulation of Angiotensin-Converting Enzyme 2 After Myocardial Infarction by Blockade of Angiotensin II ReceptorsHypertension, 2004
- Increased Angiotensin-(1-7)–Forming Activity in Failing Human Heart VentriclesCirculation, 2003
- Effects of Eprosartan Versus Enalapril in Hypertensive Patients on the Renin-Angiotensin-Aldosterone System and Safety Parameters: Results from a 26-Week, Double-blind, Multicentre StudyCurrent Medical Research and Opinion, 1999
- Hemodynamic and Humoral Effects of the Angiotensin II Antagonist Losartan in Essential HypertensionAmerican Journal of Hypertension, 1994
- Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure.Circulation, 1993